| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2a topline data readout example | NEO100 (intranasal), NEO100-01 recurrent IDH1-mutant high-grade glioma Fast TrackOrphanRare Pediatric | Phase 2a | — | Subscribe to access the data. | Biologics | Oncology | |
Phase 2a topline data readout example | NEO100 (intranasal), NEO100-01 recurrent IDH1-mutant high-grade glioma Fast TrackOrphanRare Pediatric | Phase 2a | — | Subscribe to access the data. | Biologics | Oncology | |
Phase 2a topline data readout example | NEO100 (intranasal), NEO100-01 recurrent IDH1-mutant high-grade glioma Fast TrackOrphanRare Pediatric | Phase 2a | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
NeOnc Technologies Holdings, Inc.$4.49
0 (0%)
D 28Pipeline Score Richly Valued Biotech · Clinical
Market Cap
138.91 M
EPS
-1.84
P/E Ratio
-
Value Trade
213.02 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
1.29 M
Operating CF
-6.99 M
Total Assets
3.33 M
Total Liabilities
16.56 M
Equity
-13.23 M
D/E Ratio
12,345
-4.98 %
Week
4.09 %
1 Month
-39.28 %
3 Month
-10.25 %
6 Month
-78.64 %
5 Year
-78.64 %
All Time
Cash Data
Cash Position
138.60 K
Monthly Burn
2.33 M
Runway
0 mo
Burn Trend
SEC Filing
May 15, 2026
Overview
Volume
35.03 K
52 Week Range
3.20 - 12.99
% held by Insiders
91.78 %
% held by Institutions
11.74 %
Enterprise Value
139.12 M
Total Shares
26.01 M
Short %
3.59 %
Float Shares
10.90 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for NeOnc Technologies Holdings, Inc.
89Total events
10Upcoming
24Tier-1 (high impact)
2025 – 2026Coverage
Upcoming catalysts 10
Sep 2026
T1Topline Readout
Expect preliminary NEO100 Phase 2a data readout in approximately five months
Event history 79
Jul 2026
◆Topline ReadoutNEO100Clinical Data
Topline results from NEO100-01 Phase 2a trial
recurrent IDH1-mutant high-grade gliomasource ↗
Jun 17, 2026
▲IND ClearanceNEO212IND
Abu Dhabi IND authorization for NEO212
aggressive brain tumors, including glioblastomasource ↗
Jun 17, 2026
▲Primary CompletionNEO212Trial
Phase 1 dose-escalation study completed
aggressive brain tumors, including glioblastomasource ↗
Jun 17, 2026
▲Enrollment CompleteNEO100Trial
Phase 2a study enrollment completed
recurrent IDH1-mutant high-grade glioma and related brain cancerssource ↗
Jun 16, 2026
▲IND ClearanceNEO212IND
Department of Health – Abu Dhabi granted IND authorization for NEO212
aggressive brain tumorssource ↗
Jun 16, 2026
▲Enrollment CompleteNEO100Trial
Full enrollment achieved in Phase 2a study of NEO100
recurrent IDH1-mutant high-grade glioma and related brain cancerssource ↗
Jun 16, 2026
▲Primary CompletionNEO212Trial
Phase 1 dose escalation completed, RP2D selected at 610 mg
recurrent glioblastoma and brain metastasessource ↗
Jun 2026
▲IND ClearanceNEO212IND
UAE IND authorization for NEO212
aggressive brain cancers and other malignanciessource ↗
May 12, 2026
◆Topline ReadoutNEO100Clinical Data
Full data readout six months post-enrollment
recurrent WHO Grade III/IV IDH1-mutant astrocytomasource ↗
Drug Pipeline Intelligence
D28
Pipeline Score $2M
Pipeline ValueRichly Valued
Valuation Signal3
Drugs Scored0.0x
rNPV / MCap Top 30%
Micro Cap (rank 639 of 911)
Percentile RankNeOnc Technologies Holdings, Inc. faces pipeline headwinds (28/100), with $85M risk-adjusted pipeline value, led by NEO100 in Residual, Progressive or Recurrent Grade II or III Meningioma (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NEO100 Small molecule | Residual, Progressive or Recurrent Grade II or III Meningioma | Phase 2 | NCT05023018 | 52% | $60M | RECRUITING | 30 | STALLED | D (23) | Jun 30, 2027 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NEO212 | aggressive brain tumors, including glioblastoma | Phase 1 | 2026-06-17 | 610 mg as the recommended Phase 2 dose | NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212 Read More | |
NEO212 | aggressive brain tumors, including glioblastoma | Phase 1 | 2026-06-17 | 610 mg as the recommended Phase 2 dose | NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212 Read More | |
NEO212 | aggressive brain tumors, including glioblastoma | Phase 1 | 2026-06-17 | 610 mg as the recommended Phase 2 dose | NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NTHI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NTHI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NTHINeOnc Ignites Explosive Summer: 4 New Research Reports + UAE/Dubai Drug Approval Fuel Breakout Momentum
NeOnc Technologies Holdings has secured its second Investigational New Drug (IND) authorization in the UAE for its lead therapy NEO100, aimed at treating recurrent high-grade gliomas. This authorization includes multiple clinical protocols and follows a recent IND for NEO212. The company anticipates reporting Phase 2a trial results soon, which could influence future regulatory discussions.
Read more →NTHINeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
NeOnc Technologies has received UAE IND approval for its lead candidate NEO100, allowing for expanded clinical trials across adult and pediatric populations. This approval complements ongoing U.S. development and positions NeOnc to advance multiple studies in parallel. The company anticipates reporting significant Phase 2a trial data by July 2026, which could influence future regulatory opportunities.
Read more →NTHI▼ -7.1%on this newsshared move
NeOnc's Global Expansion Accelerates After Abu Dhabi IND Approval for NEO212
NeOnc Technologies Holdings has received Investigational New Drug (IND) approval for NEO212 in Abu Dhabi, marking a significant step in its global expansion efforts. This approval follows a successful Phase 1 study and opens new clinical pathways outside the U.S. The company is also preparing for important data readouts from its NEO100 program, which targets recurrent brain cancers. Insider buying and increased institutional interest further highlight investor confidence in NeOnc's innovative therapies.
Read more →NTHIBrain Cancer Innovator NeOnc Heads into Critical Data Season with Fresh Abu Dhabi IND
NeOnc Technologies Holdings has received Investigational New Drug authorization for NEO212, enhancing its clinical development for aggressive brain tumors. The company is also seeing promising results from its NEO100 program, which has shown tumor remission in a subset of patients. Insider buying by the CEO suggests confidence in the company's trajectory as it approaches critical data releases.
Read more →NTHINeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development
NeOnc Technologies has secured Investigational New Drug (IND) approval for NEO212 in the UAE, following successful Phase 1 trials. The recommended Phase 2 dose has been established at 610 mg, and the company is optimistic about expanding its clinical development internationally. This approval marks a significant milestone as NeOnc continues discussions with the U.S. FDA for a potential registrational pathway.
Read more →NTHI▲ +14.9%on this newsshared move
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development Clearance enables Phase 2 evaluation of NEO212, the Company's oral perillyl alco
NeOnc Technologies has received Investigational New Drug (IND) approval for NEO212 from the Department of Health - Abu Dhabi, following a successful Phase 1 trial. The approval allows the company to proceed to Phase 2 evaluation of its oral perillyl alcohol-temozolomide conjugate, which aims to treat aggressive brain tumors. NeOnc is hopeful that this international clearance will assist in discussions with the U.S. FDA regarding a potential registrational pathway. However, several conditions must be met before patient enrollment can begin in the UAE.
Read more →NTHIThe Next Great AI Revolution May Be Drug Delivery
The article discusses the transformative role of AI in drug delivery, particularly for CNS diseases. NeOnc Technologies is highlighted for its efforts to overcome the blood-brain barrier, a significant challenge in treating brain cancers like glioblastoma. The convergence of AI and healthcare is creating new opportunities for innovative drug delivery systems, attracting investor interest in the biotech sector. However, challenges remain, including low survival rates for glioblastoma and the early stage of sector development.
Read more →NTHINeOnc Technologies Gains Growing Institutional Support Ahead of Key Brain Cancer Clinical Milestones
NeOnc Technologies has garnered increased institutional support as it advances its brain cancer therapies. Analysts from Maxim Group and BTIG Research have initiated coverage with positive ratings, reflecting confidence in the company's pipeline. Insider buying from CEO Amir Heshmatpour further indicates management's belief in the upcoming clinical milestones. NeOnc is developing innovative drug delivery technologies aimed at overcoming challenges in neuro-oncology.
Read more →NTHINeOnc Provides Business Update and Reports Q1 2026 Financial Results
NeOnc Technologies Holdings, Inc. reported positive advancements in its clinical programs during Q1 2026, particularly for NEO212 and NEO100. The company observed early signs of clinical activity in patients and is preparing for a pivotal Phase 2 study with regulatory engagement from the FDA. Additionally, operational improvements were highlighted, including executive team expansions and financial stability through new funding. The upcoming interim data readout is anticipated to further validate NEO100's therapeutic potential.
Read more →NTHINeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
NeOnc Technologies Holdings, Inc. CEO Amir Heshmatpour has increased his investment in the company by over $500,000, reflecting confidence in upcoming clinical milestones. The company is advancing its NEO100 Phase 2a study for recurrent IDH1-mutant high-grade glioma, with an interim analysis expected later this year. Heshmatpour's investment underscores his belief in the potential of NeOnc's therapies to improve patient outcomes.
Read more →NTHINeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results
NeOnc Technologies Holdings, Inc. announced that Chairman and CEO Amir Heshmatpour purchased around $300,000 in company stock, reflecting confidence in its undervalued shares. The company is anticipating key developments, including interim data for NEO100 and a Type B End-of-Phase FDA meeting for NEO212. Despite a reported net loss of $62 million in 2025, management emphasizes ongoing clinical advancements and disciplined capital allocation.
Read more →NTHINeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results Insider buying indicates management's conviction in underv
NeOnc Technologies Holdings, Inc. recently revealed that Chairman and CEO Amir Heshmatpour purchased around $300,000 worth of NTHI stock, indicating management's confidence in the undervalued shares amidst multiple upcoming catalysts. In its 2025 fiscal report, the company posted a net loss of approximately $62 million, primarily from non-cash stock-based compensation and one-time advisory fees. The firm completed a financing round raising $13 million to strengthen its balance sheet and continues focusing on advancing clinical programs aimed at CNS cancers.
Read more →NTHI▼ -13.1%on this news
NeOnc Provides Business Update and Reports Q4 2025 Financial Results
NeOnc Technologies Holdings, Inc. announced its Q4 2025 financial results and highlighted several operational achievements. The company reported promising early data from its NEO212 and NEO100 studies, showcasing potential anti-tumor activity and significant remission rates without major toxicity. NeOnc has also bolstered its finances with a $10 million PIPE financing and is advancing its leadership team and growth strategy. Looking ahead, the company anticipates important milestones, including an FDA meeting for NEO212 and an upcoming data readout for NEO100.
Read more →NTHINeOnc Technologies Appoints David Choi as Chief Accounting Officer
NeOnc Technologies Holdings, Inc. has announced the appointment of David Choi as its Chief Accounting Officer. Mr. Choi will oversee the company's financial operations as NeOnc accelerates its clinical trials and expands globally. With over a decade of experience in accounting and financial reporting, his expertise is expected to bring value to the company's financial governance. This appointment comes at a crucial time as NeOnc develops therapies targeting central nervous system cancers.
Read more →NTHINeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management Hosted KOL Conference Call
NeOnc Technologies announced positive results from the Phase 1 dose-escalation trial for NEO212, establishing the Recommended Phase 2 Dose at 610 mg. The trial showed promising signs of clinical efficacy in patients with recurrent GBM and brain metastases. The company plans to transition into Phase 2 to further assess efficacy and engage with the FDA for potential accelerated approval pathways.
Read more →NTHINeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m.
NeOnc Technologies announced positive results from its Phase 1 dose-escalation trial for NEO212, its oral bio-conjugated therapy for CNS cancers. The trial confirmed the Maximum Tolerated Dose (MTD) at 810 mg and established the Recommended Phase 2 Dose at 610 mg. Early clinical efficacy signs in recurrent GBM and brain metastases patients were observed. The company aims to engage the FDA to discuss the next steps for a pivotal Phase 2 study, potentially reshaping the treatment landscape for aggressive CNS malignancies.
Read more →NTHINeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity
NeOnc Technologies is set to host an investor conference call on March 4, 2026, to discuss the dose-escalation results from its Phase 1 trial of the NEO212-01 study. The management team will present safety and toxicity data alongside pharmacokinetic findings. The company is focused on central nervous system cancers and is advancing its proprietary bioconjugated temozolomide platform under FDA Fast-Track and IND status.
Read more →NTHITop Entrepreneurs Going into 2026
The article discusses the evolving landscape of entrepreneurship as we approach 2026. It highlights a shift from a growth-at-all-costs mentality to a focus on credibility and sustainable business practices. Featured entrepreneurs, including Amir Heshmatpour and Barry Boatner, exemplify this trend by prioritizing trust and adaptability in their leadership styles.
Read more →NTHINeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management
NeOnc Technologies has secured a PIPE investment led by Cinctive Capital Management, amounting to $10 million. This investment is expected to enhance NeOnc's clinical trials and support its development of therapies for central nervous system cancers. The funding will also assist in repaying debts and bolstering working capital.
Read more →NTHINeOnc Technologies Reports Updated Clinical Results
NeOnc Technologies has reported updated clinical results for its intranasal NEO100 therapy in patients with recurrent Grade III/IV IDH1-mutant astrocytoma. The expanded cohort of 25 patients shows a 24% radiographic remission rate and 44% six-month progression-free survival. Notably, 36% of patients have survived for over 18 months post-treatment, with no significant toxicity reported. These findings suggest NEO100 may offer a significant advancement in treatment options for this patient population.
Read more →NTHINeOnc Technologies Reports Updated Clinical Results Expanded Clinical Experience Demonstrates Additional Long-Term Survival and Radiographic Remission in Recurrent Grade III/IV IDH1-Mutant Astrocytoma Treated with Intran
NeOnc Technologies reports positive updated clinical results from its ongoing Phase 1/2a study of intranasal NEO100 for recurrent Grade III/IV IDH1-mutant astrocytoma. The expanded cohort of 25 patients demonstrated a 24% radiographic remission rate, which is significantly higher than the typical response to salvage therapies. Additionally, 44% of patients achieved six-month progression-free survival, while 36% remained alive 18 months post-treatment initiation. The findings suggest NEO100 may represent a meaningful advancement in treating this challenging cancer.
Read more →NTHINeOnc Technologies (Nasdaq: NTHI) Announces AI-Driven Findings Showing Ultrasound Enhances the Potency of an Already Effective NEO100 in Treating Primary and Metastatic Brain Tumors
NeOnc Technologies announced positive preclinical findings from a collaboration with USC, revealing that ultrasound enhances the effectiveness of its drug NEO100 in treating both primary and metastatic brain tumors. This study highlights NEO100's potential as a leading sonodynamic therapy, validated by AI techniques predicting its performance. The use of rapid 3D bioprinting technology allows quicker generation of tumor organoids, aligning with objectives to reduce animal testing. The company aims to advance NEO100 into clinical trials, indicating a significant opportunity for broader therapeutic applications.
Read more →NTHINeOnc Technologies Completes Enrollment in Pivotal NEO100 Phase2a Trial for IDH-1 mutant Recurrent High‑Grade Glioma and Expects Interim Data Readout in SixMonths (Q22026)
NeOnc Technologies has completed patient enrollment in its NEO100-1 Phase 2a trial for recurrent IDH1-mutant high-grade glioma. The company expects to report preliminary data in approximately six months. The trial's completion is viewed as a significant milestone, following positive interim results that suggest NEO100's potential for effective treatment. NeOnc aims to leverage this data to enhance its position in CNS oncology.
Read more →NTHINeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update
NeOnc Technologies Holdings reported its financial results for Q3 2025, highlighting advancements in therapies for CNS cancers. The company noted major clinical achievements, including encouraging Phase 2a data for the NEO100 program and FDA clearance for the NEO212 asset. They secured a $50 million commitment to support expansion efforts, particularly in the Middle East. With a reinforced leadership team and promising pipeline, NeOnc aims to provide novel treatment options while delivering shareholder value.
Read more →NTHINeOnc Technologies Reports Updated Clinical Results Results of Clinical Trials Provide Evidence Supporting Significant Radiographic Response and Potential Long-Term Survival in Recurrent Grade III/IV IDH1-Mutant Astrocyt
NeOnc Technologies has announced updated clinical results from trials involving 24 patients with recurrent Grade III/IV IDH1-mutant astrocytoma treated with intranasal NEO100. The trials demonstrated a significant radiographic response in 21% of patients, along with a 44% six-month progression-free survival rate, which is notably higher than historical averages. Additionally, 33% of patients were still alive 18 months post-treatment, and no significant toxicity was reported, suggesting NEO100's potential as a new therapeutic option for this patient population. The company believes these findings could signify a paradigm shift in treating recurrent brain cancer.
Read more →NTHINeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program
NeOnc Technologies Holdings, Inc. (NTHI) is set to host an investor conference call on November 12, 2025, to present data updates from the ongoing NEO100-1 Phase 1/2a clinical trial and compassionate use program. The focus will be on evaluating the intranasal delivery of NEO100 in patients suffering from recurrent high-grade malignant glioma. Participants will discuss MRI-based radiographic responses and trends in progression-free and overall survival outcomes. This event highlights the company's commitment to advancing brain-penetrant therapeutics aimed at addressing serious CNS disorders.
Read more →NTHINeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth
NeOnc Technologies has appointed Amir Heshmatpour as CEO, effective immediately, as part of a strategic leadership transition. Previously serving as President, Heshmatpour will continue to drive the company's mission to advance its clinical programs aimed at CNS cancers. Dr. Thomas Chen will remain closely involved as Chief Medical Officer, focusing on clinical development. The company recently secured a significant $50 million partnership and is working on pioneering therapeutic candidates through its proprietary NEO platform.
Read more →NTHIHis Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies’ Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment
NeOnc Technologies has announced that His Highness Sheikh Nahyan bin Zayed Al Nahyan will become the Executive Chairman of its subsidiary, NuroMENA. This strategic move aims to enhance the development of treatments for brain cancer and central nervous system malignancies. The partnership is expected to leverage significant resources to improve patient outcomes globally.
Read more →NTHI▲ +6.9%on this news· ran to +19% by day 3shared move
His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment CALABASAS, Calif. and ABU DHABI, United A
His Highness Sheikh Nahyan bin Zayed Al Nahyan has been appointed as the Executive Chairman of NuroMENA Holdings, the UAE subsidiary of NeOnc Technologies. This move is seen as a strategic partnership to advance the development of therapies for brain cancer and central nervous system malignancies. The collaboration aims to leverage resources from one of the world's largest sovereign wealth funds to drive healthcare innovation. NeOnc Technologies is focused on overcoming the blood-brain barrier with its NEO drug development platform and is currently conducting Phase II clinical trials for its therapeutic candidates.
Read more →NTHINeOnc Technologies: From Survival Mode To Expansion Mode
NeOnc Technologies Holdings is transitioning from survival to expansion mode, driven by a $50M partnership with Quazar. This funding is expected to alleviate financial challenges, enabling the company to advance its brain cancer treatments, NEO100 and NEO212, currently in Phase I/II trials. Despite financial struggles, the partnership signals a positive shift in NeOnc's outlook.
Read more →NTHINeOnc Technologies’ Subsidiary, NuroMENA, Signs Master Services Agreement with M42’s IROS and Expands Board of Directors
NeOnc Technologies Holdings, Inc. has made significant strides in its expansion into the Middle East through its subsidiary, NuroMENA, signing a Master Services Agreement with IROS, a UAE-based contract research organization. This partnership aims to accelerate the clinical development of NeOnc's cancer therapies. Additionally, NuroMENA is expanding its Board of Directors to include key partners from Quazar Investment, enhancing its governance and strategic direction.
Read more →NTHINeOnc Technologies' Subsidiary, NeuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors CALABASAS, Calif. and ABU DHABI, United Arab Emirates - NeOnc Technologies Holdings, Inc. (NTHI) (
NeOnc Technologies Holdings, Inc. (NTHI) has announced significant strategic developments with its subsidiary, NeuroMENA. The company signed a Master Services Agreement with IROS, an entity of M42, allowing faster clinical trial processes in the Middle East. Concurrently, the board of NeuroMENA will be expanded to include two new members from Quazar Investment to enhance leadership and operational effectiveness in the region. These moves aim to accelerate the introduction of new cancer therapies.
Read more →NTHINeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd Following Final UAE Tax Approvals
NeOnc Technologies Holdings, Inc. announced a significant partnership with Quazar Investment, set to close a $50 million deal by October 23, 2025. The partnership follows the completion of necessary regulatory approvals in the UAE and focuses on advancing NeOnc's clinical trials for CNS cancers. Key aspects of the collaboration include funding for trials and infrastructure development across the MENA region. Notably, the partnership is aimed at launching four clinical trials, including pediatric brain cancer programs, supported by an expanded Scientific Advisory Board and advanced clinical facilities in the UAE.
Read more →NTHI▲ +5.8%on this newsshared move
NeOnc Technologies Appoints Dr. David M. Ashley, Director of The Preston Robert Tisch Brain Tumor Center at Duke, to Scientific Advisory Board
NeOnc Technologies has appointed Dr. David M. Ashley to its scientific advisory board, enhancing its capabilities in neuro-oncology. Dr. Ashley, a distinguished professor at Duke University, brings extensive experience in brain tumor research. His expertise is expected to strengthen NeOnc's pipeline, particularly its lead candidates NEO100 and NEO212, which are currently in Phase II trials.
Read more →NTHINeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, to Its Scientific Advisory Board
NeOnc Technologies has appointed Dr. Alexandra M. Miller to its Scientific Advisory Board. Dr. Miller, a leading expert in neuro-oncology at NYU Langone Health, will contribute her expertise in liquid biopsy assays and tumor genomics. This appointment coincides with NeOnc's expansion of its global trial network, aimed at advancing its clinical trials for CNS cancer therapies.
Read more →NTHINeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board
NeOnc Technologies has appointed Dr. Henry S. Friedman, a leading neuro-oncologist, to its scientific advisory board. His expertise will support the advancement of NeOnc's clinical pipeline, particularly the NEO100 and NEO212 candidates. The company aims to enhance confidence among stakeholders and improve treatment options for patients with CNS cancers.
Read more →NTHINeOnc Technologies to Showcase Progress on Addressing Brain Cancer to 63 Million TV Households on “Health Uncensored with Dr. Drew” on the Lifetime Network on September 25, premiering nationwide at 8:00 a.m. ET/PT
NeOnc Technologies will be featured on 'Health Uncensored with Dr. Drew' on September 25, showcasing its advancements in brain cancer therapies. The episode will highlight the company's NEO™ platform technology, which aims to overcome the Blood-Brain Barrier. Key milestones include a $50 million partnership and FDA authorization for a Phase II trial of NEO212. The feature aims to raise awareness and share patient success stories.
Read more →NTHI▲ +17.1%on this news
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212
NeOnc Technologies has received FDA authorization to advance its NEO212 clinical trial into Phase IIa/IIb after a successful Phase I study. NEO212 combines Temozolomide with a proprietary molecule to improve treatment for glioblastoma. Patient enrollment is set to begin by the end of 2025, with trials expanding to major cancer centers across the U.S.
Read more →NTHI▲ +17.1%on this newsshared move
NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 - A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer
NeOnc Technologies has received FDA authorization to proceed with its Phase II clinical trials for NEO212, an innovative oral chemotherapy candidate for brain cancer. This follows a successful Phase I dose-escalation study confirming safe administration. NEO212 combines Temozolomide with NeOnc's proprietary NEO100, aiming to enhance treatment efficacy and overcome current therapeutic limitations. Patient enrollment for the trial is expected to begin by the end of 2025 at major cancer centers across the U.S.
Read more →NTHINeOnc Reports Second Quarter 2025 Results
NeOnc Technologies Holdings, Inc. reported its Q2 2025 financial results, highlighting a $50 million strategic partnership and $2.5 million in NIH funding. The company is advancing its clinical pipeline, with full enrollment for NEO100-01 expected by September 2025. Despite a net loss increase, NeOnc is positioned for growth with new leadership and expanded visibility in the market.
Read more →NTHINeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update CALABASAS, Calif. and ABU DHABI, United Arab Emirates
NeOnc Technologies Holdings, Inc. has reported its financial results for the second quarter of 2025, highlighting significant operational achievements. Key milestones include the advancement of its clinical pipeline for CNS cancers and the initiation of a pediatric trial. The company has formed a strategic partnership worth $50 million and has been added to the Russell Microcap Index, reinforcing its growth trajectory. Expectations for pivotal trial updates and FDA readouts are set for late 2025 and early 2026.
Read more →NTHI▲ +6.7%on this news
NeOnc Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment.
NeOnc Technologies Holdings, Inc. has finalized all contingencies for a $50 million investment from Quazar Investment, following the incorporation of NuroMENA Holdings Ltd. This strategic partnership aims to enhance the development of CNS therapies across the MENA region, particularly focusing on the NEO212 and NEO100 clinical programs. The collaboration is seen as a significant step towards delivering innovative treatments for CNS cancers.
Read more →NTHINeOnc Awarded $2.5 Million in NIH STTR Grants
NeOnc Technologies Holdings, Inc. has been awarded two NIH STTR grants totaling $2.5 million to advance its therapeutic compound NEO212. The funding will support preclinical studies in acute myelogenous leukemia and expand clinical development into gliomas. This funding marks a significant milestone as the company approaches the end of its Phase 1 trial for NEO212.
Read more →NTHINeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia
NeOnc Technologies Holdings, Inc. has been awarded $2.5 million in NIH STTR grants to advance its therapeutic compound NEO212, which is aimed at treating gliomas and leukemia. This funding will support the ongoing transition from Phase 1 clinical trials to anticipated Phase 2 trials. The collaboration is structured to leverage both NeOnc's capabilities and its academic partners, highlighting the growing momentum of the company's innovative research and development efforts in treating central nervous system malignancies.
Read more →NTHINeOnc Technologies Featured on Yahoo Finance’s Podcast Trader Talk
NeOnc Technologies Holdings, Inc. was featured on Yahoo Finance's Trader Talk podcast, discussing its advancements in brain cancer treatments and its recent achievements. The company has secured a significant partnership and joined the Russell Microcap Index, showcasing its growth despite market challenges. The podcast also highlights NeOnc's innovative approaches, including intranasal drug delivery and AI's potential impact on biotech.
Read more →NTHINeOnc To Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri
NeOnc Technologies Holdings, Inc. has signed a Letter of Intent to acquire an IP portfolio from Dr. Ishwar K. Puri, which includes U.S. Patent No. 11,788,057 B2. The portfolio features technologies in 3D bioprinting, AI, and quantum modeling aimed at enhancing drug discovery for brain cancers. Dr. Puri will also join NeOnc's Board, contributing his extensive research experience.
Read more →NTHI▼ -7.8%on this newsshared move
NeOnc Signs Definitive Agreement for $50 Million Strategic Partnership
NeOnc Technologies Holdings, Inc. has signed a definitive agreement for a $50 million strategic partnership with Quazar Investment. This partnership aims to expand NeOnc's presence in the MENA region and fund Phase 2B clinical trials. The agreement includes the acquisition of shares and the establishment of critical infrastructure to support neuro-oncology solutions. NeOnc's CEO highlighted the transformative nature of this partnership for global expansion.
Read more →NTHI▼ -7.8%on this newsshared move
NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment
NeOnc Technologies has entered into a $50 million strategic partnership with Quazar Investment to expand its operations and improve clinical trial capabilities in the MENA region. The agreement, which involves the acquisition of 1.4 million shares at $25 each, will provide funding for ongoing research and development of treatments for brain and central nervous system cancers. This partnership marks a significant step for NeOnc as it aims to accelerate its global presence and enhance patient access to innovative neuro-oncology therapies.
Read more →NTHI▲ +6.1%on this newsshared move
NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference
NeOnc Technologies Holdings, Inc. will participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. The company focuses on developing treatments for brain and central nervous system cancers, with its NEO100 and NEO212 therapeutics currently in Phase II clinical trials. Investors can schedule meetings with management through BTIG representatives.
Read more →NTHI▼ -5.1%on this newsshared move
NeOnc’s Executive Chairman To Be Featured In Live Interview
NeOnc Technologies Holdings, Inc. announced that its Executive Chairman, Amir Heshmatpour, will be featured in a live interview, highlighting the company's recent achievements. This includes a $50 million partnership with Quazar Investment and inclusion in the Russell Microcap Index. The company focuses on developing treatments for brain and central nervous system cancers.
Read more →NTHINeOnc Executes Sub-License Agreement With Quazar Investment
NeOnc Technologies Holdings, Inc. has signed a Sub-License Agreement with Quazar Investment, marking a significant step in their strategic transaction. This agreement covers the UAE and MENA region for their drug candidates NEO100 and NEO212. The partnership aims to raise $50 million for clinical trials and infrastructure development. However, the transaction's completion depends on fulfilling several conditions within 120 days.
Read more →NTHINeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar Investment
NeOnc Technologies Holdings, Inc. has executed a Sub-License Agreement with its subsidiary, NuroCure, as part of a $50 million strategic partnership with Quazar Investment. This agreement marks a significant milestone towards completing the transaction necessary for raising funds aimed at expanding operations in the MENA region. The partnership is expected to enhance market liquidity and enable the advancement of innovative therapies for brain and central nervous system cancers. However, the finalization of the partnership is still conditional on meeting pre-established criteria within a specified timeframe.
Read more →NTHI▼ -18.1%on this news· ran to -30% by day 3
NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership
NeOnc Technologies has received Board approval for a $50 million strategic partnership with Quazar Investment, marking a significant step towards expanding its operations in the MENA region. This investment will support clinical trials and infrastructure development. NeOnc aims to complete remaining conditions within 120 days to finalize the transaction.
Read more →NTHINeOnc Technologies Holdings, Inc. Joins Russel Microcap® Index
NeOnc Technologies Holdings, Inc. has been added to the Russell Microcap Index following the 2025 annual reconstitution. This inclusion is seen as a validation of the company's growth and commitment to enhancing shareholder value. NeOnc is focused on developing innovative treatments for CNS cancers and is advancing its Phase I clinical trials while expanding into the MENA region.
Read more →NTHINeOnc Signs $50 Million Strategic Term Sheet With Quazar Investment
NeOnc Technologies Holdings, Inc. has signed a non-binding term sheet with Quazar Investment to establish a new investment platform in the UAE, focusing on clinical trials for brain cancer therapies. The partnership aims to raise $50 million for clinical development and regulatory efforts in the MENA region. This marks NeOnc's first international expansion, leveraging local clinical trial infrastructure.
Read more →NTHINeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform
NeOnc Technologies has signed a non-binding strategic term sheet with Quazar Investment for a $50 million investment aimed at launching clinical trials in the GCC and MENA regions. This partnership will establish NuroMENA Holdings Ltd, which will manage clinical trials for NeOnc's drugs, including NEO100 and NEO212, targeting aggressive brain cancers. The investment is contingent upon NeOnc satisfying certain conditions within 120 days, marking NeOnc's first international expansion in its clinical programs.
Read more →NTHINeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs USC brain tumor authority to accelerate four clinical trials including
NeOnc Technologies Holdings, Inc. has appointed Dr. Josh Neman as Chief Clinical Officer to enhance its clinical strategy and translational oncology programs. Dr. Neman, who joins from USC, has a notable background in cancer neuroscience and will lead several clinical trials, including the promising NEO100. His expertise in brain tumor biology is expected to propel the company's research and collaborations forward. This appointment is viewed as a significant step in advancing NeOnc's goal of transforming treatments for patients with CNS cancers.
Read more →NTHI▼ -8.3%on this news· ran to -22% by day 3
Building Biotech Excellence: The Growth Strategy Behind NeOnc Technologies’ Vision
NeOnc Technologies is developing a novel nasal-brain delivery system to treat brain cancer, aiming to overcome the blood-brain barrier. Led by Dr. Thomas Chen and Executive Chairman Amir F. Heshmatpour, the company is focusing on innovative solutions, including a pediatric version of their treatment currently in phase one trials. NeOnc has opted for a direct listing to support its growth strategy.
Read more →NTHINeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
NeOnc Technologies Holdings, Inc. has announced a robust global patent portfolio of 176 patents, which includes 126 issued and 50 pending. This portfolio reinforces the company’s competitive edge in developing oncology and neurology therapeutics. The patents cover key products in their pipeline, including NEO100 and NEO212, and span major pharmaceutical markets worldwide. NeOnc aims to leverage this intellectual property to advance its innovative therapies toward regulatory approval.
Read more →NTHI▼ -12.1%on this news· ran to -23% by day 3shared move
NeOnc Expects Full Enrollment In Phase 2a Trial of NEO100-01
NeOnc Technologies Holdings, Inc. anticipates full enrollment in its Phase 2a trial for NEO100-01 by September 2025, with only six patients remaining. This trial targets aggressive brain cancers, specifically IDH1 mutant gliomas, using an innovative intranasal delivery method. Early Phase 1 data suggests promising outcomes, and the therapy has received FDA designations that highlight its potential impact.
Read more →NTHI▼ -10%on this news· ran to -24% by day 3shared move
NeOnc Executive Chairman Assumes Expanded Leadership Role
NeOnc Technologies Holdings, Inc. has appointed Amir Heshmatpour as President while he continues as Executive Chairman. This move aims to enhance leadership and accelerate clinical initiatives, particularly focusing on patient enrollment for their lead drug candidates, NEO212 and NEO100. Heshmatpour's extensive experience is expected to drive the company's strategic goals forward.
Read more →NTHI▼ -10%on this news· ran to -24% by day 3shared move
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President
NeOnc Technologies Holdings, Inc. has announced that Amir Heshmatpour, the Executive Chairman, will assume the role of President, in addition to his existing responsibilities. The appointment aims to enhance leadership as the company advances its clinical programs for central nervous system cancers. Heshmatpour's 25 years of executive experience, including significant capital markets expertise, is seen as crucial for driving the company’s strategic direction and improving patient enrollment in clinical trials. NeOnc's drug candidates are currently undergoing Phase II trials and are supported by an extensive patent portfolio.
Read more →NTHINeOnc Nears Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
NeOnc Technologies Holdings, Inc. has announced that its Phase I clinical trial for NEO212, a novel brain cancer therapy, is nearing completion of enrollment. This therapy combines temozolomide and perillyl alcohol, aiming to enhance treatment efficacy while reducing systemic side effects. The trial's final cohort is expected to complete dosing soon, marking a significant milestone in the drug's development.
Read more →NTHI▼ -19.3%on this news· ran to -42% by day 3
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100
NeOnc Technologies Holdings, Inc. announced that the FDA has granted Rare Pediatric Disease Designation to NEO100 for treating pediatric-type diffuse high-grade gliomas. This designation highlights the urgent need for treatment options in this area. The company aims to advance NEO100 through clinical trials and collaborate with the medical community to improve outcomes for affected children.
Read more →NTHINeOnc Technologies Partners with CBCC Global Research for Clinical Trials on NEO100-01
NeOnc Technologies has partnered with CBCC Global Research to enhance its clinical trial capabilities in India for the NEO100-01 glioblastoma study. This collaboration aims to facilitate patient enrollment and expedite the development of a novel therapy targeting aggressive brain tumors. The trials will be conducted under strict FDA-compliant standards, ensuring high-quality data generation.
Read more →NTHIUSC-licensed Startup NeOnc Technologies Celebrates NASDAQ Listing
NeOnc Technologies, a USC-licensed startup, has made its debut on Nasdaq, marking a significant milestone in its journey. The company focuses on treating brain tumors with its innovative intranasal drug delivery system, NEO100, currently in phase 2 clinical trials. Additionally, NeOnc has partnered with CBCC Global Research to expand its clinical trials across 30 FDA-compliant sites in India, enhancing patient recruitment and regulatory compliance.
Read more →NTHINeOnc Technologies Holdings Announces Effectiveness
NeOnc Technologies Holdings, Inc. has announced that its registration statement for public direct listing on the Nasdaq Global Market has been declared effective by the SEC. The company anticipates that its common stock will begin trading under the ticker symbol 'NTHI' on March 26, 2025. NeOnc is focused on developing therapeutics for central nervous system conditions and has products in Phase II clinical trials. The announcement highlights its innovative drug development platform and patent protections extending to 2038.
Read more →NTHINeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments WESTLAKE VILLAGE, Calif.
NeOnc Technologies has entered a partnership with CBCC Global Research to enhance its clinical trial capabilities in India, particularly for the NEO100-01 study targeting glioblastoma. This collaboration is aimed at increasing patient enrollment and ensuring compliance with FDA regulations. The trials will be executed following Good Clinical and Laboratory Practices to maintain data quality. NeOnc's executives highlight the importance of this partnership for bringing innovative cancer therapies to market and addressing the needs of a diverse patient population.
Read more →NTHINeOnc Technologies Holdings Announces SEC S-1 Registration For Anticipated On NASDAQ
NeOnc Technologies Holdings, Inc. announced that its SEC Form S-1 registration statement has been declared effective, allowing for a public direct listing of its common stock on the Nasdaq Global Market under the ticker symbol NTHI. The anticipated trading start date is March 26, 2025. The company focuses on developing therapeutics for central nervous system conditions and has promising drug candidates in clinical trials.
Read more →NTHINeOnc Technologies Holdings, Inc. Appoints Dr. Victoria Medvec to Board of Directors
NeOnc Technologies Holdings, Inc. has appointed Dr. Victoria Medvec to its Board of Directors. Dr. Medvec, CEO of Medvec and Associates, brings significant experience in mergers, acquisitions, and strategic partnerships. Her expertise is expected to support NeOnc's mission to develop therapies for central nervous system conditions, particularly brain tumors.
Read more →NTHINeOnc Technologies Appointments Dr. Steven L. Giannotta to its Board of Directors
NeOnc Technologies has appointed Dr. Steven L. Giannotta to its Board of Directors. Dr. Giannotta, a renowned neurosurgeon with extensive experience in cerebrovascular surgery, will contribute his expertise to advance the company's mission. His background includes pioneering therapies and significant clinical achievements, which are expected to enhance NeOnc's innovative solutions in neurosurgical care.
Read more →NTHINeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors
NeOnc Technologies Holdings, Inc. has appointed Jimmy Delshad to its Board of Directors. Delshad, a former mayor of Beverly Hills and a global ambassador for Cedars Sinai International, brings over 20 years of consulting experience. His expertise in strategic growth and community engagement is expected to bolster NeOnc's efforts in developing therapies for brain and CNS diseases.
Read more →NTHINeOnc Technologies Holdings, Inc. Appoints Dr. Alan Chiang to Board of Directors
NeOnc Technologies Holdings, Inc. has appointed Dr. Alan Chiang to its Board of Directors, enhancing its expertise in neurosurgery and biotechnology. Dr. Chiang, a prominent neurosurgeon and entrepreneur, will contribute significantly to the company's mission of advancing its patented drug, NEO100. His extensive experience in clinical research and innovation is expected to drive NeOnc's growth in central nervous system therapeutics.
Read more →NTHINASDAQ’S Opening Bell Will Ring For USC Research Startup
NeOnc Technologies Holdings Inc., a USC-licensed startup, will celebrate its direct listing on Nasdaq by ringing the opening bell. The company focuses on treating malignant gliomas with its proprietary drug NEO100, currently in phase 2 clinical trials. This listing marks a pivotal milestone for NeOnc and underscores the importance of university collaborations in advancing medical innovations.
Read more →NTHIPioneering a New Era in Brain Cancer Treatment with NASDAQ Listing
NeOnc Technologies Holdings has listed on the NASDAQ Global Market under the ticker NTHI, marking a significant milestone in its mission to innovate brain cancer treatments. The company focuses on developing advanced drug delivery systems and therapies to improve patient outcomes. Its intranasal delivery method and extensive patent portfolio position it as a leader in CNS disease treatment. The listing is expected to facilitate growth, partnerships, and regulatory advancements.
Read more →NTHINeOnc Technologies Holdings, Inc. Appoints Bader Almonawer to Board of Directors
NeOnc Technologies Holdings, Inc. has appointed Bader Almonawer to its Board of Directors. Almonawer, a seasoned finance professional, brings valuable experience in capital markets and M&A. His expertise is expected to support NeOnc's mission of developing innovative therapies for central nervous system diseases. The company is advancing its drug candidates in clinical trials.
Read more →NTHINEO100 Research Shows Impact On Recurrent Grade 4 Astrocytoma
A study on NEO100, an intranasal therapy for recurrent grade 4 astrocytoma, demonstrated promising results. A 40-year-old patient experienced continuous tumor regression over 13 months after using NEO100 daily. The treatment was well-tolerated, with no serious side effects reported, indicating its potential as a viable option for glioma patients.
Read more →NTHIHealthcare Entrepreneurs Express Hope, Concern Over RFK Jr. Confirmation
Healthcare entrepreneurs have mixed feelings about Robert F. Kennedy Jr.'s confirmation as FDA Head. While some express hope for improved efficiency in drug approvals and increased funding for preventive health, others worry that his skepticism towards vaccines may hinder development and investment in that area. The potential for faster federal grant turnaround is seen as a positive aspect.
Read more →NTHINEO100 Intranasal Delivery Technology Shows Promise for Better Therapeutic Results.
The article highlights the potential of NEO100, an intranasal delivery technology, to improve treatment outcomes for patients with astrocytoma and glioblastoma. Traditional treatments face challenges due to the blood-brain barrier, but NEO100 may provide a more effective route to target brain tumors. Phase 1 studies are complete, and Phase 2a trials are currently underway to assess its impact on tumor growth.
Read more →NTHIExpanding Horizons: NeOnc Technologies’ Bold Vision
NeOnc Technologies is advancing neuro-oncology with a novel nasal delivery system aimed at treating glioblastoma. Led by Dr. Thomas Chen, the company focuses on overcoming the blood-brain barrier to enhance drug delivery. With a strong patent portfolio and a commitment to patient-centered care, NeOnc is preparing for a public listing to expand its market reach.
Read more →NTHINeOnc Technologies: The Future of Neurosurgery | New Frontiers
NeOnc Technologies is revolutionizing neurosurgery with a non-invasive intranasal drug delivery system aimed at treating aggressive brain cancers. Founded by Dr. Thomas Chen, the company focuses on therapies like NEO100 and NEO212, which target glioblastoma multiforme while minimizing side effects. The upcoming documentary will highlight these advancements and their impact on patient care, set to air in 2025.
Read more →NTHIA Nose For Attacking Brain Cancer
NeOnc Technologies' CEO, Dr. Thomas Chen, discussed the company's innovative approach to treating brain cancer on the Bio Report Podcast. The firm utilizes a natural compound from essential oils that can cross the blood-brain barrier and kill cancer cells. This method also allows for the delivery of additional therapies, addressing a significant challenge in brain cancer treatment.
Read more →NTHIRevolutionizing The Fight Against Cancer
Dr. Thomas Chen, CEO of NeOnc Technologies, is pioneering a novel platform technology aimed at delivering therapeutics directly to the brain, potentially improving treatment efficacy for brain cancer and CNS disorders. His extensive qualifications and experience in neurosurgery and research bolster the company's mission to revolutionize cancer treatment. NeOnc's advancements may significantly impact patient outcomes in neuro-oncology.
Read more →NTHIDisrupting Biotech: The Business Model Behind NeOnc Technologies
NeOnc Technologies is innovating brain cancer treatment with a nasal inhalation method that bypasses the blood-brain barrier. Their lead compound, NEO 100, has shown promise in early trials. The company is progressing through clinical trials, including a Phase 2A trial, while adapting its business strategy to market conditions. NeOnc aims for a sustainable approach to biotech success.
Read more →NTHIRevolutionizing Biotech: How NeOnc Technologies Is Striving To Transform Brain Cancer Treatment And Drive Industry Innovation
NeOnc Technologies is innovating brain cancer treatment with a new nasal-brain delivery system aimed at improving drug efficacy for glioblastoma patients. Founded by Dr. Thomas Chen, the system allows drugs to bypass the blood-brain barrier, potentially prolonging patient lives. Clinical trials are showing encouraging results, and the FDA has granted Fast Track designation for the treatment.
Read more →NTHIFocused on Development of Innovative Drug Delivery Solutions
NeOnc Technologies Holdings, Inc. is advancing the development of its NEO-100 intranasal delivery platform, designed to bypass the blood-brain barrier and deliver therapies for brain cancer and CNS disorders. Founded by Dr. Chen, the company is focused on addressing critical unmet needs in these areas. Ongoing Phase I and Phase II clinical trials demonstrate their commitment to innovative solutions.
Read more →NTHIEmpowering Cancer Patients: NeOnc’s Home-Based Treatment Gives Control Back
NeOnc has developed a home-based treatment for brain cancer patients that utilizes a nasal-brain delivery system. This innovative approach allows patients to inhale a compound that directly targets the brain, potentially extending their lives and reducing side effects. Currently in clinical trials, the treatment offers a more comfortable alternative to traditional methods, significantly improving the quality of life for patients.
Read more →NTHIThe Man Behind The Mission: Dr. Thomas Chen’s Vision For Brain Cancer Treatment
Dr. Thomas Chen, founder of NeOnc and a leading neurosurgeon, is pioneering a nasal-brain delivery system aimed at treating glioblastoma and other aggressive brain cancers. This innovative approach allows medications to bypass the blood-brain barrier, potentially improving patient outcomes. Dr. Chen's work combines clinical practice, research, and education, reflecting his commitment to advancing brain cancer treatment.
Read more →NTHIInnovative Strategy: NeOnc’s Bold Move In Biotech
NeOnc is advancing its unique intranasal delivery system for brain cancer treatment, currently in phase II trials. The system effectively bypasses the blood-brain barrier, leading to improved patient outcomes. The FDA has approved the inclusion of grade 3 astrocytoma patients due to the drug's success. NeOnc aims to transform brain cancer treatment through innovation and collaboration.
Read more →NTHIHow Professors Can Foster Innovation Amongst The Students They Teach
The article discusses how college professors can cultivate an innovative mindset among students. It emphasizes the importance of critical thinking, practical application of skills, and collaborative learning. By integrating technology and hands-on experiences, educators can inspire students to think creatively and prepare them for future challenges. The piece advocates for a shift from rote memorization to experiential learning.
Read more →NTHIPharmacy Focus – Oncology Edition: Advancing Brain Cancer Research and Treatment
The article discusses advancements in brain cancer treatment through NeOnc's nasal delivery system for chemotherapeutics. Dr. Thomas Chen, a neurosurgery expert, highlights the potential of their lead candidate, NEO100, in clinical trials. The innovative approach aims to bypass the blood-brain barrier, offering new hope for patients with brain cancers.
Read more →NTHIUna Empresa De Biotecnología Que Se Abre Paso A Través De La Nariz.
NeOnc Technologies is advancing its intranasal drug NE0100 for treating aggressive brain cancers, including glioblastoma. The company is shifting from a traditional IPO to a direct listing due to low investor interest. Initial trials have shown NE0100 to be safe and well-tolerated, with ongoing studies targeting specific genetic mutations.
Read more →NTHIA Biotech Going Through The Nose To Treat The Brian Plots Alternative Path To Public Markets
NeOnc Technologies is preparing for a direct public listing while conducting mid-stage trials of its intranasal brain cancer drug, NEO100. The company aims to navigate the blood-brain barrier using a novel delivery method, which has shown promise in early trials. Despite challenges in the biotech IPO market, NeOnc is optimistic about its unique approach to treating glioblastoma.
Read more →NTHINeOnc Wins Drug Delivery Technology Of The Year: A New Era In Cancer Treatment
NeOnc has developed a groundbreaking nasal spray technology that delivers cancer drugs directly to the brain via the olfactory nerve pathway. This innovative approach has won the Drug Delivery Technology of the Year award and is currently in phase 2A clinical trials. Early results indicate it may extend the lives of terminal brain cancer patients, with some experiencing tumor reduction. The company is optimistic about future FDA approval.
Read more →NTHINeOnc: A Novel Approach To Treating Brain Cancer
NeOnc Technologies is developing innovative drug delivery methods to treat brain cancer, particularly glioblastoma. Their platform, NE0100, enhances drug penetration across the blood-brain barrier, showing promising results in ongoing clinical trials. The company is also focusing on pediatric brain tumors, aiming to improve treatment effectiveness and quality of life through non-invasive therapies. Collaborations with various medical networks are set to accelerate clinical evaluations.
Read more →NTHIQ&A: Groundbreaking Intranasal Brain Cancer Treatment Bypasses Blood-Brain Barrier
NeOnc's NEO100 is a novel intranasal treatment for brain cancer that bypasses the blood-brain barrier using olfactory nerve pathways. This innovative delivery method enhances drug efficacy while minimizing side effects, particularly for high-grade gliomas. The therapy is still in clinical trials, but it shows promise for improving patient outcomes and could revolutionize treatment for other neurodegenerative conditions.
Read more →NTHINew Approaches And Greater Access To Cancer Care
NeOnc Technologies is advancing brain cancer treatment through a Phase 2 clinical study of its drug candidate, NEO100. The trial aims to demonstrate safety and biological effects while addressing challenges in delivering treatments across the blood-brain barrier. Additionally, the article highlights the urgent need for improved cancer care access in low-income countries, particularly in India, where cancer cases are rising significantly.
Read more →NTHIMeet The Surgeon Leading A Biotech Revolution: Dr. Thomas Chen’s Fight Against Brain Cancer
Dr. Thomas Chen, a neurosurgeon and director at USC, leads NeOnc, Inc. in developing a nasal brain delivery system for cancer treatment. This innovative approach aims to bypass the blood-brain barrier, potentially improving outcomes for brain cancer patients. While still in clinical trials, early results show promise, with some patients experiencing significant improvements.
Read more →NTHINeOnc – A New Company And New Approach To Brain Cancer
NeOnc Technologies has initiated a Phase 2 trial for NEO100-02, targeting meningioma patients. This trial aims to evaluate the safety and biological effects of NEO100, utilizing an innovative intranasal delivery method to enhance drug efficacy. The company has a robust pipeline with concurrent trials for various CNS cancers, highlighting its commitment to addressing treatment challenges.
Read more →NTHINeOnc Begins Enrollment for Phase 2 Clinical Trial of NEO100-02
NeOnc Technologies has initiated enrollment for its Phase 2 clinical trial of NEO100-02, targeting high-grade meningioma. This trial aims to assess the safety and biological effects of NEO100, a drug developed using NeOnc's proprietary technology. Meningiomas, which are common brain tumors, often present significant treatment challenges, especially in difficult-to-access areas.
Read more →NTHINeOnc Technologies Receives California Investment Forum’s Breakthrough Medical Technology Achievement Award
NeOnc Technologies Holdings Inc. was awarded the Breakthrough Medical Technology Achievement Award by the California Investment Forum for its innovative work in treating brain and central nervous system diseases. The award was presented by California State Treasurer Fiona Ma at the 2024 CIF Innovation Awards ceremony. NeOnc aims to elevate the standard of care for primary brain tumors through its NEO drug development platform.
Read more →NTHIFrom Terminal To Thriving: Real Patient Outcomes With NeOnc’s Treatment.
NeOnc's innovative intranasal drug delivery system is currently in clinical trials and has shown remarkable efficacy in treating brain cancer. Developed by Dr. Thomas Chen, this system allows medications to bypass the blood-brain barrier, offering hope to patients with recurrent tumors. The treatment has already demonstrated the potential to prolong lives and even reduce tumor sizes in some cases, leading to expanded trial eligibility by the FDA.
Read more →NTHINeOnc Noses Into Novel Brain Cancer Treatment
NeOnc, a biotech company founded by Dr. Thomas Chen, is developing novel nasal spray treatments for brain cancer that aim to overcome the blood-brain barrier. The company is currently in clinical trials for two products using perillyl alcohol, one of which is in phase 2 testing. NeOnc has received FDA fast-track and orphan drug status, and plans to seek partnerships with larger pharmaceutical companies after positive trial results.
Read more →NTHINeOnc Initiates Cohort 3 in Phase 1 Clinical Trial of NEO212
NeOnc Technologies has initiated Cohort 3 in its Phase 1 clinical trial for NEO212, a novel hybrid drug aimed at treating malignant brain tumors. Following the successful completion of the first two cohorts, the company is optimistic about the drug's potential to enhance treatment efficacy compared to standard therapies. The trial is part of a broader effort to address challenges in brain cancer treatment.
Read more →NTHIHealing At Home: How NeOnc’s Innovative Treatment Brings Brain Cancer Care To Patients’ Doorsteps.
NeOnc has developed a non-invasive nasal delivery system for brain cancer drugs, allowing treatment to bypass the blood-brain barrier. This innovative method enables patients to receive care at home, potentially revolutionizing brain cancer treatment. The lead drug, NEO100, has shown promising results in Phase I trials and is advancing to Phase IIa with a fast-track designation from the FDA.
Read more →NTHIVenture Capital Post Discusses NeOnc’s Path To A Direct Public Offering
NeOnc Technologies Holdings, Inc. is exploring a direct public offering after withdrawing its IPO plans. The company is valued at $220 million and is advancing its nasal delivery system for brain cancer treatment, which has received FDA fast-track designation. Despite the risks associated with direct listings, NeOnc's executive team is optimistic about their innovative approach and recent accolades.
Read more →NTHIRevolutionizing Brain Cancer Treatment: NeOnc Introduces First Non-Invasive Intranasal Drug Delivery for Brain Cancer.
NeOnc has introduced a groundbreaking non-invasive intranasal drug delivery system for brain cancer treatment, aiming to bypass the blood-brain barrier. Currently in Phase II trials, this innovative approach shows promise in prolonging the lives of patients with recurrent brain cancer. The treatment has received fast track designation from the FDA, expediting its approval process.
Read more →NTHIPioneering Non-Invasive Treatments: NeOnc’s Breakthrough In Brain Cancer Care.
NeOnc has developed a groundbreaking intranasal medication delivery system for brain cancer treatment, led by Dr. Thomas Chen. This innovative approach aims to bypass the blood-brain barrier, delivering cancer-fighting drugs directly to the brain. Currently in Phase II FDA trials, early results indicate significant patient benefits, including tumor reduction.
Read more →NTHINeOnc Technologies Completes $18.5 Million Financing
NeOnc Technologies has successfully completed an $18.5 million financing round, significantly increasing its valuation to approximately $220 million. The funding will advance its Phase I and II clinical trials aimed at improving drug delivery to the brain, particularly for brain cancer therapies. The company has also secured FDA Fast-Track status for its leading drug candidates, enhancing its development prospects.
Read more →NTHINeOnc Receives Breakthrough Medical Technology Achievement Award from CIS
NeOnc Technologies Holdings, Inc. has been awarded the Breakthrough Medical Technology Achievement Award by the California Investment Forum for its advancements in treating brain and central nervous system diseases. The award was presented by California State Treasurer Fiona Ma during the 2024 CIF Innovation Awards ceremony. NeOnc's NEO™ drug development platform and intranasal delivery system were highlighted for their potential to improve treatment outcomes for brain tumors.
Read more →NTHIStudy Shows NEO400 Has Therapeutic Effect On UV-Induced Skin Damage
A study by NeOnc Technologies Holdings revealed that NEO400 effectively treats skin damage caused by ultraviolet radiation in mice. The formulation, which combines linoleic acid and perillyl alcohol, showed significant healing and protective effects, outperforming traditional remedies like Aloe Vera. The results indicate a promising therapeutic potential for NEO400 in managing UV-induced skin damage.
Read more →NTHINEO100 Enhances Entry And Therapeutic Activity Of Chimeric Antigen Receptor T Cells
A recent study published in the Journal of Neurosurgery highlights the efficacy of NEO100 in enhancing the delivery of CAR T cells to brain tumors. In an animal model, NEO100 facilitated the entry of CD19-targeted CAR T cells into the brain, resulting in long-term survival of treated mice. This suggests a promising therapeutic approach for CNS malignancies.
Read more →Competitive Position
How NTHI ranks across every disease it competes inCompetitive Position is a premium feature
See how NTHI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial